Ga-FAPI-46 PET/CT
Phase 2Small molecule
Ga-FAPI-46 PET/CT is one of 54 small molecule programs targeting Head and Neck Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Pleural Mesothelioma
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Gemzar
Johnson & JohnsonPhase 2
Volrustomig
AstraZenecaPhase 3
Standard Chemotherapy
RochePhase 3
Adriamycin
PfizerPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Fabhalta
RegeneronPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pleural Mesothelioma1 trial
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Recruiting·—·Phase 2·NCT06790082·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-FAPI-46 PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJohn O. Prior